Physician
Emergency Medicine
Dr. William L. McGuire, MD
William McGuire is an expert in the field of Emergency Medicine. He went to University of Tennessee College of Medicine. William McGuire has written publications. He has 98 publications published with PubMed. The lastest publication is: 'Estrogen receptor as an independent prognostic factor for early recurrence in breast cancer.'
Publications
- Specific protein synthesis regulated by estrogen in human breast cancer.
- Casein and alpha-lactalbumin detection in breast cancer cells by immunocytochemistry.
- An immunotoxin cytotoxic for breast cancer cells in vitro.
- P-glycoprotein expression in human breast cancer cells.
- Estrogen-induced 24K protein in MCF-7 breast cancer cells is localized in granules.
- Human breast cancer: androgen action mediated by estrogen receptor.
- Detection of a Mr 24,000 estrogen-regulated protein in human breast cancer by monoclonal antibodies.
- Progesterone receptors as a prognostic factor in Stage II breast cancer.
- Estrogen action following irradiation of human breast cancer cells.
- Estrogen regulation of specific messinger RNA's in human breast cancer cells.
- Purification of an estrogen-regulated breast cancer protein by monoclonal antibody affinity chromatography.
- Estrogen receptor as an independent prognostic factor for early recurrence in breast cancer.
- Estrogen regulation of specific proteins as a mode of hormone action in human breast cancer.
- Breast cancer prognostic factors: evaluation guidelines.
- Autoradiographic localization of prolactin receptors in 7,12-dimethylbnez[a]anthracene-induced rat mammary carcinoma.
- Adjuvant therapy of node-negative breast cancer: another point of view.
- Estrogen receptor interaction with the antitumor agent estradiol mustard.
- Emerging impact of flow cytometry in predicting recurrence and survival in breast cancer patients.
- Breast cancer prognosis in a mixed Caucasian-Hispanic population.
- Loss of heterozygosity in breast cancer: cause or effect?
- Chemotherapy drug resistance--a panel discussion.
- Oncogenes in clinical cancer--a panel discussion.
- Treatment of stage III breast cancer. A panel discussion.
- The role of growth factors in breast cancer. A panel discussion.
- In vitro assays to predict drug sensitivity and drug resistance. A panel discussion.
- Colony-stimulating factors. A panel discussion.
- Megestrol acetate in breast cancer--a panel discussion.
- Pain control in breast cancer. A panel discussion.
- New biologic prognostic factors in breast cancer.
- Prognostic factors for recurrence and survival in human breast cancer.
- Resistance to endocrine therapy. A panel discussion.
- A 46-kDa antigen associated with estrogen receptor in human breast cancer.
- Adjuvant therapy in node-negative breast cancer. A panel discussion.
- Autologous bone marrow transplantation in breast cancer. A panel discussion.
- Prognostic significance of progesterone receptor levels in estrogen receptor-positive patients with metastatic breast cancer treated with tamoxifen: results of a prosp...
- A simple polymerase chain reaction method for detection and cloning of low-abundance transcripts.
- Prognostic indicators in invasive breast cancer.
- Insulin-like growth factor-I receptors are overexpressed and predict a low risk in human breast cancer.
- Estrogen regulation of growth and specific protein synthesis in human breast cancer cells in tissue culture.
- Chromosomal assignments of human 27-kDa heat shock protein gene family.
- Prognostic factors in breast cancer.
- Overexpression of HER-2/neu and its relationship with other prognostic factors change during the progression of in situ to invasive breast cancer.
- Steroid receptors and other prognostic factors in primary breast cancer.
- Electrophoretic analysis of 248 clinical breast cancer specimens for P-glycoprotein overexpression or gene amplification.
- Development of polyclonal and monoclonal antibodies to iodinated contrast media.
- P-glycoprotein gene amplification or overexpression is not detected in clinical breast cancer specimens.
- The ER-positive/PgR-negative breast cancer phenotype is not associated with mutations within the DNA binding domain.
- DNA ploidy, S-phase, and steroid receptors in more than 127,000 breast cancer patients.
- How to integrate steroid hormone receptor, flow cytometric, and other prognostic information in regard to primary breast cancer.
- Prognosis of breast cancer patients: how to use what?
- Induction of the estrogen-regulated "24K" protein by heat shock.
- Prognostic factors for recurrence and survival in axillary node-negative breast cancer.
- DNA flow cytometry and prognostic factors in 1331 frozen breast cancer specimens.
- Prognosis and treatment decisions in patients with breast cancer without axillary node involvement.
- Prognostic factors and treatment decisions in axillary-node-negative breast cancer.
- Treatment decisions in axillary node-negative breast cancer patients.
- Inhibition of estrogen receptor action by a naturally occurring variant in human breast tumors.
- Follow-up study of HER-2/neu amplification in primary breast cancer.
- Variant human breast tumor estrogen receptor with constitutive transcriptional activity.
- P-glycoprotein and progesterone receptor in human breast cancer.
- Estrogen receptor gene methylation in human breast tumors.
- Association of the 323/A3 surface glycoprotein with tumor characteristics and behavior in human breast cancer.
- Ploidy, proliferative activity and prognosis. DNA flow cytometry of solid tumors.
- Uptake of the noncytotoxic transport probe procainamide in the Chinese hamster ovary model of multidrug resistance.
- DNA flow cytometry and other prognostic factors in breast cancer.
- Isolation and characterization of an adriamycin-resistant breast tumor cell line.
- Evaluation of a modeling system for S-phase estimation in breast cancer by flow cytometry.
- A cDNA for the estradiol-regulated 24K protein: control of mRNA levels in MCF-7 cells.
- Flow cytometry, cellular DNA content, and prognosis in human malignancy.
- Estrogen receptor variants in clinical breast cancer.
- Abnormal oestrogen receptor in clinical breast cancer.
- Abnormal estrogen receptor in clinical breast cancer.
- The importance of normal and abnormal oestrogen receptor in breast cancer.
- Prognostic factors and therapeutic decisions in axillary node-negative breast cancer.
- Neural Network Analysis of DNA flow cytometry histograms.
- Prognostic significance of p53 gene alterations in node-negative breast cancer.
- Estrogen receptor, progesterone receptor, and HER-2/neu protein in breast cancers from pregnant patients.
- Measurement of steroid hormone receptors in breast cancer patients on tamoxifen.
- Estrogen receptor mutations in breast cancer.
- Response of human breast cancer cells to heat shock and chemotherapeutic drugs.
- Expression of HER-2/neu oncoprotein in human breast cancer: a comparison of immunohistochemical and western blot techniques.
- Why do so many prognostic factors fail to pan out?
- A demonstration that breast cancer recurrence can be predicted by neural network analysis.
- Tamoxifen and the isomers of 4-hydroxytamoxifen in tamoxifen-resistant tumors from breast cancer patients.
- Cathepsin D and prognosis in breast cancer.
- Steroid receptors, cellular kinetics, and lymph node status as prognostic factors in breast cancer.
- Prediction of relapse or survival in patients with node-negative breast cancer by DNA flow cytometry.
- Prognosis in breast cancer.
- HER-2/neu oncogene protein and prognosis in breast cancer.
- Estrogen receptor expression in human breast cancer associated with an estrogen receptor gene restriction fragment length polymorphism.
- Sensitive detection of estrogen receptor RNA by polymerase chain reaction assay.
- How to use prognostic factors in axillary node-negative breast cancer patients.
- Optimal mastectomy timing.
- Progesterone receptor gene restriction fragment length polymorphisms in human breast tumors.
- Heat shock protein hsp70 in patients with axillary lymph node-negative breast cancer: prognostic implications.
- Biological and clinical implications of heat shock protein 27,000 (Hsp27): a review.
- Prognostic indicators in early breast cancer.
Schools
University of Tennessee Memphis College of Medicine amp Surgery
Meth Cen
Methodist Hsp Central Unit
Doctors Specialties
- Emergency Medicine
Accepted Insurances
Education
-
University of Tennessee College of Medicine
Drug Facts
| NPI NUMBER | 1164401618 | |
| NPPES Provider LastName | MCGUIRE | |
| NPPES Provider FirstName | WILLIAM | |
| NPPES Provider ZIPCode | 383013901 | |
| NPPES Provider State | TN | |
| Specialty Description | Emergency Medicine | |
| Total Claim Count | 111.0 | |
| Distinct Opioid Count | 1.0 | |
| Opioid Claim Count | 32.0 | |
| Percent Opioid Claims | 28.83 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1164401618 |
| Last Name Of The Provider | MCGUIRE |
| First Name Of The Provider | WILLIAM |
| View All |
Similar Doctors
|
Dr. Joe M. Harris, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Jerry D. Peters, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Donald B. Hatcher, DO
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Robert E. Turner III, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Stephen G. Bergquist, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Donald C. Correll, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Hans S. Bez, DO
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Stephen E. Johnston, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Jackie L. Taylor, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Thomas C. Farrar, MD |